CIRSE Registry for SIR-Spheres Therapy

CompletedOBSERVATIONAL
Enrollment

1,051

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 1, 2018

Study Completion Date

January 1, 2020

Conditions
Liver Carcinoma
Interventions
DEVICE

Yttrium-90 loaded SIR-Spheres microspheres

Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.

BEHAVIORAL

QLQ-C30 with HCC module

In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.

Trial Locations (1)

1010

Cardiovascular and Interventional Radiological Society of Europe, Vienna

All Listed Sponsors
lead

Cardiovascular and Interventional Radiological Society of Europe

OTHER

NCT02305459 - CIRSE Registry for SIR-Spheres Therapy | Biotech Hunter | Biotech Hunter